CAD20.38
1.29% today
Toronto, Apr 02, 08:57 pm CET
ISIN
CA0717051076
Symbol
BLCO
Sector

Bausch + Lomb Stock price

CAD20.12
-2.97 12.86% 1M
-5.68 22.02% 6M
-5.84 22.50% YTD
-3.12 13.43% 1Y
-5.38 21.10% 3Y
-5.38 21.10% 5Y
-5.38 21.10% 10Y
Toronto, Closing price Tue, Apr 01 2025
-0.75 3.59%
ISIN
CA0717051076
Symbol
BLCO
Sector

Key metrics

Market capitalization CAD7.09b
Enterprise Value CAD13.84b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.11
P/S ratio (TTM) P/S ratio 1.08
P/B ratio (TTM) P/B ratio 0.76
Revenue growth (TTM) Revenue growth 17.32%
Revenue (TTM) Revenue CAD6.57b
EBIT (operating result TTM) EBIT CAD320.24m
Free Cash Flow (TTM) Free Cash Flow CAD-80.83m
Cash position CAD454.47m
EPS (TTM) EPS CAD-1.23
P/E forward negative
P/S forward 1.00
EV/Sales forward 1.95
Short interest 0.07%
Show more

Is Bausch + Lomb a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Bausch + Lomb Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Bausch + Lomb forecast:

7x Buy
47%
7x Hold
47%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Bausch + Lomb forecast:

Buy
47%
Hold
47%
Sell
7%

Financial data from Bausch + Lomb

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
6,567 6,567
17% 17%
100%
- Direct Costs 2,961 2,961
17% 17%
45%
3,607 3,607
18% 18%
55%
- Selling and Administrative Expenses 2,219 2,219
21% 21%
34%
- Research and Development Expense 470 470
8% 8%
7%
917 917
16% 16%
14%
- Depreciation and Amortization 597 597
16% 16%
9%
EBIT (Operating Income) EBIT 320 320
16% 16%
5%
Net Profit -431 -431
23% 23%
-7%

In millions CAD.

Don't miss a Thing! We will send you all news about Bausch + Lomb directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Head office Canada
CEO Brenton Saunders
Employees 13,500
Founded 1853
Website www.bausch.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today